ClinicalTrials.Veeva

Menu
S

South Oklahoma Heart Research, LLC | Oklahoma City, OK

Research site

Site insights

Top conditions

Top treatments

Apixaban
Bococizumab
Empagliflozin
Inclisiran
Tovinontrine
CER-001
K-877
Ziltivekimab
IONIS-AGT-LRx
sodium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Julie White

Verified by this site

Active trials

21 of 69 total trials

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Active, not recruiting
Heart
Heart Failure With Preserved Ejection Fraction (HFPEF)
Drug: VS-041
Other: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneousl...

Enrolling
Heart Failure
Other: Sham-Control
Device: Alleviant ALV1 System

Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe...

Enrolling
Mitral Incompetence
Mitral Valve Regurgitation
Device: AltaValve

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Active, not recruiting
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Ziltivekimab
Drug: Placebo

This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatm...

Enrolling
Mitral Incompetence
Mitral Valve Regurgitation
Device: AltaValve System.
Status recently updated

A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval m...

Enrolling
Active, not recruiting
Hypertension
Hypertension, Essential
Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Enrolling
Worsening Heart Failure
Drug: COR-1167
Drug: Placebo

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling
Hypertension
Cardiovascular Diseases
Drug: Placebo matching Vicadrostat
Drug: Vicadrostat

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Active, not recruiting
Arteriosclerosis
Hypercholesterolaemia
Drug: Enlicitide Decanoate
Drug: Placebo

This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions p...

Active, not recruiting
Ischemic Heart Disease
Coronary Artery Disease
Device: Orbital Atherectomy
Device: Balloon

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in...

Enrolling
Acute Decompensated Heart Failure
Device: Reprieve System
Drug: furosemide infusion

The Impella ECP Study is a prospective, multi-center, single-arm study evaluating the rate of major adverse cardiovascular and cerebrovascular events...

Invitation-only
High-Risk Percutaneous Coronary Intervention
Device: Impella ECP

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous co...

Enrolling
Peripheral Endovascular Intervention
Percutaneous Coronary Intervention
Drug: Normal Saline (Placebo)
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF...

Enrolling
Heart Failure With Preserved Ejection Fraction
Obesity
Drug: Placebo
Drug: Maridebart cafraglutide

This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diab...

Active, not recruiting
Diabetic Cardiomyopathies
Drug: AT-001
Drug: Placebo

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF)...

Active, not recruiting
Stroke
Atrial Fibrillation (AF)
Drug: Rivaroxaban
Biological: Abelacimab

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in part...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Drug: JK07
Drug: Placebo

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and hi...

Enrolling
Severe Hypertriglyceridemia
Drug: Plozasiran
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Pfizer logo
Abbott logo
Kowa logo
Novo Nordisk logo
4
A
Arrowhead Pharmaceuticals logo
Bayer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems